骨代谢指标物在骨质疏松症诊疗中的应用进展

被引：13

作者：

朱传美

机构：

[1] 四川大学华西医院门诊部

来源：

华西医学 | 2015年 / 30卷 / 08期

关键词：

骨代谢指标物; 骨质疏松症; 骨密度; 骨强度;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

骨质疏松症(OP)属于全球重要健康问题,主要以骨量减低、骨微结构损坏、以致骨脆性增加,骨折风险增高为特点。依照世界卫生组织标准,通过双能X线检测骨密度仍是目前诊断OP及判断其严重程度的金标准。然而,由于骨密度并非影响骨强度的唯一因素,且具有结果相对恒定,对干预疗效的反应不够灵敏等不足之处,体现骨重建水平的骨代谢标志物则在一定程度上起到了与骨密度相辅相成的作用,对OP的辅助诊断、疗效监测以及治疗方案的选择方面起到了良好的作用。不仅如此,由于骨密度不适宜频繁检测而缺乏对患者给予相应的正向疗效反馈,导致OP患者依从性较低。而定期检查骨代谢标志物,可行性好,通过其动态变化情况可提高依从性,使患者坚持治疗。现就临床上较为常用的几种骨代谢指标作一综述。

引用

页码：1567 / 1570

页数：4

共 22 条

[1]

Circulating Osteogenic Precursor Cells in Type 2 Diabetes Mellitus [J].

Manavalan, J. S. ;

Cremers, S. ;

Dempster, D. W. ;

Zhou, H. ;

Dworakowski, E. ;

Kode, A. ;

Kousteni, S. ;

Rubin, M. R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) :3240-3250

[2]

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges [J].

Bauer, D. ;

Krege, J. ;

Lane, N. ;

Leary, E. ;

Libanati, C. ;

Miller, P. ;

Myers, G. ;

Silverman, S. ;

Vesper, H. W. ;

Lee, D. ;

Payette, M. ;

Randall, S. .

OSTEOPOROSIS INTERNATIONAL, 2012, 23 (10) :2425-2433

[3]

Bone Turnover Markers and Bone Mineral Density Response With Risedronate Therapy: Relationship With Fracture Risk and Patient Adherence [J].

Eastell, Richard ;

Vrijens, Bernard ;

Cahal, David L. ;

Ringe, Johann D. ;

Garnero, Patrick ;

Watts, Nelson B. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (07) :1662-1669

[4]

Control of RANKL gene expression.[J].Charles A. O'Brien.Bone.2009, 4

[5]

Common biochemical markers of bone turnover predict future bone loss: A 5-year follow-up study.[J].Owe Löfman;Per Magnusson;Göran Toss;Lasse Larsson.Clinica Chimica Acta.2005, 1

[6]

Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells [J].

Hernández, MV ;

Guañabens, N ;

Alvarez, L ;

Monegal, A ;

Peris, P ;

Riba, J ;

Ercilla, G ;

de Osaba, MJM ;

Muñoz-Gómez, J .

CALCIFIED TISSUE INTERNATIONAL, 2004, 74 (03) :284-293

[7]

Interim report and recommendations of the World Health Organization task-force for osteoporosis [J].

Genant, HK ;

Cooper, C ;

Poor, G ;

Reid, I ;

Ehrlich, G ;

Kanis, J ;

Nordin, BEC ;

Barrett-Connor, E ;

Black, D ;

Bonjour, JP ;

Dawson-Hughes, B ;

Delmas, PD ;

Dequeker, J ;

Eis, SR ;

Gennari, C ;

Johnell, O ;

Johnston, CC ;

Lau, EMC ;

Liberman, UA ;

Lindsay, R ;

Martin, TJ ;

Masri, B ;

Mautalen, CA ;

Meunier, PJ ;

Miller, PD ;

Mithal, A ;

Morii, H ;

Papapoulos, S ;

Woolf, A ;

Yu, W ;

Khaltaev, N .

OSTEOPOROSIS INTERNATIONAL, 1999, 10 (04) :259-264

[8]

Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia [J].

Pedersen, BJ ;

Schlemmer, A ;

Rosenquist, C ;

Hassager, C ;

Christiansen, C .

OSTEOPOROSIS INTERNATIONAL, 1995, 5 (06) :472-477

[9]

ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS - SYNOPSIS OF A WHO REPORT [J].

KANIS, JA ;

ALEXEEVA, L ;

BONJOUR, JP ;

BURKHARDT, P ;

CHRISTIANSEN, C ;

COOPER, C ;

DELMAS, P ;

JOHNELL, O ;

JOHNSTON, C ;

KANIS, JA ;

KHALTAEV, N ;

LIPS, P ;

MAZZUOLI, G ;

MELTON, LJ ;

MEUNIER, P ;

SEEMAN, E ;

STEPAN, J ;

TOSTESON, A .

OSTEOPOROSIS INTERNATIONAL, 1994, 4 (06) :368-381

[10]

NORMAL BONE PARTICLES ARE PREFERENTIALLY RESORBED IN THE PRESENCE OF OSTEOCALCIN-DEFICIENT BONE PARTICLES INVIVO [J].

DEFRANCO, DJ ;

GLOWACKI, J ;

COX, KA ;

LIAN, JB .

CALCIFIED TISSUE INTERNATIONAL, 1991, 49 (01) :43-50

← 1 2 3 →